About CMRX

Founded: 2000
Employees: 79
CEO: Michael Andriole
WebsiteView website: www.chimerix.com

Chimerix, Inc., a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases in the United States. Its product pipeline comprising dordaviprone (ONC201), which is in phase 3 clinical-stage development for H3 K27M-mutant diffuse glioma, as well as in phase 2 Investigator Initiated Clinical Trials for multiple oncology studies; and ONC206, a second generation imipridone ClpP agonist and DRD2 antagonist which is in phase 1 clinical trial to treat central nervous systems and other solid tumors. The company also develops ONC212, an imipridone, investigational agonist of the orphan GPCR tumor suppressor GPR132, as well as ClpP, which is in preclinical trial; and CMX521, a nucleoside analog antiviral drug candidate for the treatment of novel coronaviruses. In addition, it offers TEMBEXA, a lipid conjugate which acts via inhibition of viral DNA synthesis that is a medical countermeasure for smallpox. The company has license agreement with SymBio Pharmaceuticals to develop and commercialize TEMBEXA for human diseases other than orthopoxviruses, including smallpox. Chimerix, Inc. was incorporated in 2000 and is headquartered in Durham, North Carolina.

Recent CMRX News & Updates

Announcement • Mar 05

Jazz Pharmaceuticals plc (NasdaqGS:JAZZ) entered into a definitive agreement to acquire Chimerix, Inc. (NasdaqGM:CMRX) for approximately $930 million.

Jazz Pharmaceuticals plc (NasdaqGS:JAZZ) entered into a definitive agreement to acquire Chimerix, Inc. (NasdaqGM:CMRX) for approximately $930 million on March 4, 2025. Under the terms of the merger agreement, Jazz will commence an all-cash tender offer to acquire all outstanding shares of Chimerix's common stock, whereby Chimerix shareholders will be offered $8.55 per share in cash. Upon the successful completion of the tender offer, Jazz will acquire all shares not acquired in the tender through a second-step merger for the same consideration per share paid in the tender offer. Jazz expects to fund the transaction through existing cash and investments. In case of termination, Chimerix will be required to pay a termination fee of an amount in cash equal to $35,000,000. The transaction is subject to customary closing conditions, including the tender of a majority of the outstanding shares of Chimerix's voting common stock and other conditions. Chimerix's Board of Directors unanimously recommends that Chimerix shareholders tender their shares in the tender offer. The board of directors of Chimerix unanimously approved the agreement. The board of directors of Jazz Pharmaceuticals also approved the agreement and expected to close in the second quarter of 2025. Guggenheim Securities is serving as financial advisor to Jazz Pharmaceuticals, and Mark Gordon and Victor Goldfeld of Wachtell, Lipton, Rosen & Katz is serving as legal advisors. Centerview Partners LLC is serving as financial advisor as well as fairness opinion provider to Chimerix, and Graham Robinson and Laura Knoll of Skadden, Arps, Slate, Meagher & Flom LLP and Jason Kent and Kevin Cooper of Cooley LLP are serving as legal advisors.

Recent updates

No updates

Chimerix, Inc. Stock Price

CMRX Share Price Performance

CMRX Community Narratives

Trending Discussion

Recently Updated Narratives

Snowflake Analysis

Chimerix, Inc. Key Details

About CMRX

Recent CMRX News & Updates

Chimerix, Inc.(NasdaqGM:CMRX) dropped from NASDAQ Composite Index

Jazz Pharmaceuticals plc (NasdaqGS:JAZZ) entered into a definitive agreement to acquire Chimerix, Inc. (NasdaqGM:CMRX) for approximately $930 million.

Chimerix: Potential 'First' In Targeting Recurrent High-Grade Glioma Patients

Recent updates

Chimerix, Inc. Competitors

Dyne Therapeutics

Structure Therapeutics

Arcus Biosciences

Alumis